A prostaglandin compound shown by the following general formula (II): in which L and M are hydrogen, hydroxy, halogen, linear or branched C1-6 alkyl, linear or branched C1-6 hydroxyalkyl, linear C1-6 alkanoyloxy or branched or oxo, in which at least one of L and M is a different group of hydrogen, and the five-membered ring may have one or more double bonds； A is -CH3, or -CH2OH, -COCH2OH, -COOH or a salt, ether, ester or amide thereof； B is a single bond, -CH2-CH2-, -CH = CH-, -C≡C-, -CH2-CH2-CH2-, -CH = CH-CH2-, -CH2-CH = CH - C≡ C CH2-or -CH2-C≡C-； Z is X1 and X2 are hydrogen, linear or branched C1-6 alkyl or halogen； R1 is a linear or branched saturated or unsaturated C1-14 aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, aryl or a heterocyclic group, and at least one of the carbon atom in the aliphatic hydrocarbon it is optionally substituted with oxygen, nitrogen or sulfur； R2 is a straight or branched C1-6 alkylene single bond or alkylene； and R3 linear or branched C1-6 alkyl, linear or branched C1-6 alkoxy, linear or branched C1-6 alkanoyloxy, C3-6 cycloalkyl, C3-6 cycloalkyloxy, aryl, aryloxy, a heterocyclic group or a group heterocyclic oxy for use in the treatment of obesity.Un compuesto de prostaglandina mostrado por la siguiente fórmula general (II) : en la que L y M son hidrógeno, hidroxi, halógeno, alquilo C1-6 lineal o ramificado, hidroxialquilo (C1-6 lineal o ramificado), alcanoiloxi C1-6 lineal o ramificado u oxo, en la que al menos uno de L y M es un grupo distinto de hidrógeno, y el anillo de cinco miembros puede tener uno o más dobles enlaces； A es -CH3, o -CH2OH, -COCH2OH, -COOH o una sal, éter, éster o amida de los mismos； B es un enlace sencillo, -CH2-CH2-, -CH=CH-, -C&equiv；C-, -CH2-CH2-CH2-, -CH=CH-CH2-, -CH2-CH=CH--C&equiv；C CH2-o -CH2-C&equiv；C-； Z es X1 y X2 son hidrógeno, alquilo C1-6 lineal o ramificado o halógeno； R1 es un residuo hidrocarburo alifático C1-14 bivalente lineal o ra
